| SC 13G/A | 2023-01-27 | JPMORGAN CHASE & CO | Revance Therapeutics, Inc. | 4,982,949 | 6.0% | EDGAR |
| SC 13G/A | 2022-12-09 | Capital World Investors | Revance Therapeutics, Inc. | 8,463,909 | 10.3% | EDGAR |
| SC 13G/A | 2022-02-14 | Palo Alto Investors LP | Revance Therapeutics, Inc. | 4,369,366 | 6.1% | EDGAR |
| SC 13G | 2022-02-11 | Capital World Investors | Revance Therapeutics, Inc. | 3,712,000 | 5.2% | EDGAR |
| SC 13G | 2022-02-10 | VANGUARD GROUP INC | Revance Therapeutics, Inc. | 3,602,297 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-08 | GIC Private Ltd | Revance Therapeutics, Inc. | 4,176,080 | 5.8% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Revance Therapeutics, Inc. | 1,104,531 | 1.5% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | Revance Therapeutics, Inc. | 5,334,099 | 7.4% | EDGAR |
| SC 13G/A | 2022-01-18 | JPMORGAN CHASE & CO | Revance Therapeutics, Inc. | 6,794,223 | 9.4% | EDGAR |
| SC 13G/A | 2021-02-16 | ArrowMark Colorado Holdings LLC | Revance Therapeutics, Inc. | 2,964,135 | 4.5% | EDGAR |
| SC 13G/A | 2021-02-12 | GIC Private Ltd | Revance Therapeutics, Inc. | 3,830,951 | 5.8% | EDGAR |
| SC 13G/A | 2021-02-10 | Essex Woodlands Health Ventures VIII, L.L.C. | Revance Therapeutics, Inc. | 457,085 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-05 | BlackRock Inc. | Revance Therapeutics, Inc. | 5,012,352 | 7.5% | EDGAR |
| SC 13G/A | 2021-02-04 | WELLINGTON MANAGEMENT GROUP LLP | Revance Therapeutics, Inc. | 3,397,872 | 5.1% | EDGAR |
| SC 13G/A | 2021-02-02 | FRANKLIN RESOURCES INC | Revance Therapeutics, Inc. | 1,755,863 | 2.6% | EDGAR |
| SC 13G/A | 2021-01-29 | JPMORGAN CHASE & CO | Revance Therapeutics, Inc. | 4,067,042 | 6.1% | EDGAR |
| SC 13G/A | 2020-08-10 | WELLINGTON MANAGEMENT GROUP LLP | Revance Therapeutics, Inc. | 3,743,700 | 5.7% | EDGAR |
| SC 13G | 2020-03-13 | GIC Private Ltd | Revance Therapeutics, Inc. | 2,965,551 | 5.2% | EDGAR |
| SC 13G/A | 2020-02-14 | ArrowMark Colorado Holdings LLC | Revance Therapeutics, Inc. | 4,840,636 | 9.6% | EDGAR |
| SC 13G/A | 2020-02-06 | BlackRock Inc. | Revance Therapeutics, Inc. | 3,688,657 | 7.2% | EDGAR |